Lowest-Rated StocksLowest-RatedNASDAQ:REPL Replimune Group (REPL) Stock Price, News & Analysis $9.98 +1.11 (+12.51%) Closing price 04:00 PM EasternExtended Trading$9.89 -0.09 (-0.89%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Replimune Group Stock (NASDAQ:REPL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Replimune Group alerts:Sign Up Key Stats Today's Range$8.80▼$10.4250-Day Range$1.70▼$9.9852-Week Range$1.50▼$13.24Volume8.99 million shsAverage Volume8.72 million shsMarket Capitalization$824.05 millionP/E RatioN/ADividend YieldN/APrice Target$4.88Consensus RatingReduce Company Overview Replimune Group, Inc. is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses. Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation. The company’s pipeline also includes RP2, RP3 and RP4, each engineered with distinct cytokine or co‐stimulatory transgenes to address different tumor types and immune environments. Clinical studies to date have evaluated these candidates as monotherapies and in combination with checkpoint inhibitors, with initial data reported in melanoma, cutaneous squamous cell carcinoma and other solid tumors. Founded in 2015 and headquartered in Woburn, Massachusetts, Replimune designs and executes clinical trials across North America and Europe. The company’s research and manufacturing infrastructure supports rapid development and scalable production of its viral immunotherapies. Replimune maintains collaborations with academic institutions and clinical research organizations to advance its programs through late-stage studies. Replimune is led by an experienced management team and board of directors with deep expertise in oncology drug development, virology and regulatory affairs. The company’s leadership draws on years of precedent in advancing innovative cancer treatments from early discovery into pivotal clinical trials.AI Generated. May Contain Errors. Read More Replimune Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreREPL MarketRank™: Replimune Group scored higher than 28% of companies evaluated by MarketBeat, and ranked 762nd out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.9 / 5Analyst RatingReduce Consensus RatingReplimune Group has received a consensus rating of Reduce. The company's average rating score is 1.70, and is based on no strong buy ratings, no buy ratings, 7 hold ratings, and 3 sell ratings.Downside RiskReplimune Group has a consensus price target of $4.88, representing about 51.2% downside from its current price of $9.98.Amount of Analyst CoverageReplimune Group has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Replimune Group's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Replimune Group are expected to grow in the coming year, from ($3.39) to ($2.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Replimune Group is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Replimune Group is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReplimune Group has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Replimune Group's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted30.22% of the float of Replimune Group has been sold short.Short Interest Ratio / Days to CoverReplimune Group has a short interest ratio ("days to cover") of 2.83, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Replimune Group has recently increased by 11.81%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldReplimune Group does not currently pay a dividend.Dividend GrowthReplimune Group does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.39 News SentimentReplimune Group has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Replimune Group this week, compared to 9 articles on an average week.Search InterestOnly 21 people have searched for REPL on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows10 people have added Replimune Group to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Replimune Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $52,065.00 in company stock.Percentage Held by Insiders5.20% of the stock of Replimune Group is held by insiders.Percentage Held by Institutions92.53% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Replimune Group's insider trading history. Receive REPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. REPL Stock News HeadlinesReplimune Group, Inc.: Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology ...June 1 at 10:12 PM | finanznachrichten.deReplimune Group, Inc.: Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical ...June 1 at 10:12 PM | finanznachrichten.deYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.June 3 at 1:00 AM | Profits Run (Ad)Why Is REPL Stock Gaining In Pre-Market Today?June 1 at 10:12 PM | finance.yahoo.comReplimune Group Presents Final First-in-Human Data for RP2 Oncolytic Immunotherapy at ASCO 2026May 31 at 8:11 AM | quiverquant.comQReplimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual MeetingMay 31 at 8:00 AM | globenewswire.comStock Movers: Dell, Replimune, SnowflakeMay 30, 2026 | bloomberg.comReplimune soars after FDA reconsiders denial of cancer drugMay 30, 2026 | msn.comSee More Headlines REPL Stock Analysis - Frequently Asked Questions How have REPL shares performed this year? Replimune Group's stock was trading at $9.72 at the beginning of the year. Since then, REPL shares have increased by 2.7% and is now trading at $9.98. How were Replimune Group's earnings last quarter? Replimune Group, Inc. (NASDAQ:REPL) released its quarterly earnings data on Thursday, November, 6th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.87) by $0.03. When did Replimune Group IPO? Replimune Group (REPL) raised $100 million in an IPO on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO. Who are Replimune Group's major shareholders? Replimune Group's top institutional investors include Dimensional Fund Advisors LP (1.38%), EcoR1 Capital LLC (1.21%), Candriam S.C.A. (0.48%) and Renaissance Technologies LLC (0.46%). Insiders that own company stock include Robert Coffin, Philip Astley-Sparke, Colin Love, Sushil Patel, Pamela Esposito, Christopher Sarchi, Konstantinos Xynos, Tanya Lewis, Emily Luisa Hill, Andrew Schwendenman and Kapil Dhingra. View institutional ownership trends. How do I buy shares of Replimune Group? Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Replimune Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Replimune Group investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Visa (V) and Home Depot (HD). Company Calendar Last Earnings11/06/2025Today6/03/2026Next Earnings (Estimated)6/04/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 REPL's financial health is in the Green zone, according to TradeSmith. REPL has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:REPL CIK1737953 Webwww.replimune.com Phone(781) 222-9600FaxN/AEmployees210Year Founded2015Price Target and Rating Average Price Target for Replimune Group$4.88 High Price Target$12.00 Low Price Target$2.00 Potential Upside/Downside-51.2%Consensus RatingReduce Rating Score (0-4)1.70 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($3.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$247.30 million Net MarginsN/A Pretax MarginN/A Return on Equity-102.69% Return on Assets-72.22% Debt Debt-to-Equity Ratio0.33 Current Ratio5.60 Quick Ratio5.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.40 per share Price / Book1.85Miscellaneous Outstanding Shares82,570,000Free Float78,279,000Market Cap$824.05 million OptionableOptionable Beta0.91 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:REPL) was last updated on 6/3/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
